keyword
MENU ▼
Read by QxMD icon Read
search

exenatide nondiabetic

keyword
https://www.readbyqxmd.com/read/27898183/effect-of-exenatide-on-postprandial-glucose-fluxes-lipolysis-and-%C3%A3-cell-function-in-nondiabetic-morbidly-obese-patients
#1
Stefania Camastra, Brenno Astiarraga, Andrea Tura, Silvia Frascerra, Demetrio Ciociaro, Andrea Mari, Amalia Gastaldelli, Ele Ferrannini
AIMS: To investigate the effect of exenatide on glucose disposal, insulin secretion, ß-cell function, lipolysis, and hormone concentrations in non-diabetic, morbidly obese subjects under physiological conditions. MATERIALS AND METHODS: Patients were assigned to exenatide 10 µg twice daily (EXE, n = 15) or control (CT, n = 15) for 3 months. Patients received a meal test/tracer study (MTT) to measure endogenous glucose production (EGP), rate of oral glucose appearance (RaO), insulin secretion rate (ISR), ß-cell function, hepatic (HIR) and adipose tissue insulin resistance (AT-IR) and insulin sensitivity (IS)...
November 29, 2016: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/27550386/dapagliflozin-qd-and-exenatide-qw-dual-therapy-a-24-week-randomized-placebo-controlled-phase-2-study-examining-effects-on-bodyweight-and-prediabetes-in-obese-nondiabetic-adults
#2
Per Lundkvist, C David Sjöström, Sam Amini, Maria J Pereira, Eva Johnsson, Jan W Eriksson
AIMS: Dapagliflozin as well as exenatide reduce bodyweight in patients with type 2 diabetes. We explored the effects of dual therapy with these agents on bodyweight, body composition, glycemic parameters, and systolic blood pressure (SBP) in obese nondiabetic adults. MATERIALS AND METHODS: This single-center, double-blind trial randomized 50 obese nondiabetic adults (aged 18-70 years; body mass index 30-45 kg/m(2) ) to oral dapagliflozin 10 mg once daily plus subcutaneous long-acting exenatide 2 mg once weekly or placebo...
August 23, 2016: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/25580440/the-glp-1-analogue-exenatide-improves-hepatic-and-muscle-insulin-sensitivity-in-diabetic-rats-tracer-studies-in-the-basal-state-and-during-hyperinsulinemic-euglycemic-clamp
#3
COMPARATIVE STUDY
Hui Wu, Chunhua Sui, Hui Xu, Fangzhen Xia, Hualing Zhai, Huixin Zhang, Pan Weng, Bing Han, Sichun Du, Yingli Lu
OBJECTIVE: Glucagon-like peptide-1 (GLP-1) analogues (e.g., exenatide) increase insulin secretion in diabetes but less is known about their effects on glucose production or insulin-stimulated glucose uptake in peripheral tissues. METHODS: Four groups of Sprague-Dawley rats were studied: nondiabetic (control, C); nondiabetic + exenatide (C + E); diabetic (D); diabetic + exenatide (D + E) with diabetes induced by streptozotocin and high fat diet. Infusion of 3-(3)H-glucose and U-(13)C-glycerol was used to measure basal rates of appearance (Ra) of glucose and glycerol and gluconeogenesis from glycerol (GNG)...
2014: Journal of Diabetes Research
https://www.readbyqxmd.com/read/24627601/exenatide-improves-hepatic-steatosis-by-enhancing-lipid-use-in-adipose-tissue-in-nondiabetic-rats
#4
Kosuke Tanaka, Yuko Masaki, Masatake Tanaka, Masayuki Miyazaki, Munechika Enjoji, Makoto Nakamuta, Masaki Kato, Masatoshi Nomura, Toyoshi Inoguchi, Kazuhiro Kotoh, Ryoichi Takayanagi
AIM: To investigate the metabolic changes in skeletal muscle and/or adipose tissue in glucagon-like peptide-1-induced improvement of nonalcoholic fatty liver disease (NAFLD). METHODS: Male Wistar rats were fed either a control diet (control group) or a high-fat diet (HFD). After 4 wk, the HFD-fed rats were subdivided into two groups; one group was injected with exenatide [HFD-Ex(+) group] and the other with saline [HFD-Ex(-) group] every day for 12 wk. The control group received saline and were fed a control diet...
March 14, 2014: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/24249759/glucagon-like-peptide-1-receptor-agonists-for-weight-loss-in-adult-patients-without-diabetes
#5
REVIEW
Anne Ottney
PURPOSE: The efficacy and safety of glucagon-like peptide (GLP)-1 receptor agonists for weight loss in adult patients without diabetes is reviewed. SUMMARY: GLP-1 receptor agonists have been associated with significant weight loss in patients with diabetes, raising the question of whether these agents could be used for weight loss in patients without diabetes. The mechanism by which GLP-1 receptor agonists induce weight loss is believed to be related to multiple actions involving the brain and gastrointestinal tract, with the primary action related to an increase in satiety...
December 1, 2013: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/23393696/treatment-of-obese-diabetics
#6
REVIEW
Stepán Svacina
Fat accumulation is a typical phenomenon in the pathogenesis of Type 2 diabetes. Also Type 1 diabetics are getting obese these days living in an environment with typical caloric overfeeding and low physical activity. Weight reduction is an important part of therapy in all obese diabetic patients. Orlistat is the only accessible antiobesity drug today. Weight neutral antidiabetics like metformin and DPP-4 inhibitors can be also used. Incretin analogues (exenatide and liraglutide) are also very important drugs inducing weight loss in diabetic and also in nondiabetic patients...
2012: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/23191935/exenatide-as-a-novel-weight-loss-modality-in-patients-without-diabetes
#7
REVIEW
Jessica L Moreno, Kristine C Willett, Alicia R Desilets
OBJECTIVE: To evaluate the potential role of exenatide for weight loss in overweight or obese adults without diabetes. DATA SOURCES: PubMed (1946-August 2012) and EMBASE (1974-August 2012) were used to conduct a literature search utilizing the terms exenatide, weight loss, obesity, and overweight. Additional references were identified by bibliographic review of relevant articles. STUDY SELECTION AND DATA EXTRACTION: Studies assessing the use of exenatide in adult subjects without type 2 diabetes or polycystic ovary syndrome and reporting effects on body weight were included...
December 2012: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/22735035/alterations-in-energy-balance-following-exenatide-administration
#8
David P Bradley, Roger Kulstad, Natalie Racine, Yoram Shenker, Melissa Meredith, Dale A Schoeller
Exenatide is a medication similar in structure and effect to native glucagon-like peptide-1, an incretin hormone with glucose-lowering properties. The aim of the study was to measure the change in total energy expenditure (TEE) and body composition during exenatide administration and by deduction the relative contributions of energy expenditure and energy intake to exenatide-induced weight loss. Forty-five obese (body mass index, 30-40 kg·m⁻²) subjects were identified. After exclusion criteria application, 28 subjects entered into the study and 18 subjects (12 female, 6 male) completed the study, which consisted of 6 visits over 14 weeks and injection of exenatide for an average of 84 ± 5 days...
October 2012: Applied Physiology, Nutrition, and Metabolism, Physiologie Appliquée, Nutrition et Métabolisme
https://www.readbyqxmd.com/read/22076596/exenatide-as-a-weight-loss-therapy-in-extreme-pediatric-obesity-a-randomized-controlled-pilot-study
#9
RANDOMIZED CONTROLLED TRIAL
Aaron S Kelly, Andrea M Metzig, Kyle D Rudser, Angela K Fitch, Claudia K Fox, Brandon M Nathan, Mary M Deering, Betsy L Schwartz, M Jennifer Abuzzahab, Laura M Gandrud, Antoinette Moran, Charles J Billington, Sarah J Schwarzenberg
The objective of this pilot study was to evaluate the effects of exenatide on BMI (primary endpoint) and cardiometabolic risk factors in nondiabetic youth with extreme obesity. Twelve children and adolescents (age 9-16 years old) with extreme obesity (BMI ≥1.2 times the 95th percentile or BMI ≥35 kg/m(2)) were enrolled in a 6-month, randomized, open-label, crossover, clinical trial consisting of two, 3-month phases: (i) a control phase of lifestyle modification and (ii) a drug phase of lifestyle modification plus exenatide...
February 2012: Obesity
https://www.readbyqxmd.com/read/22040840/short-term-exenatide-treatment-leads-to-significant-weight-loss-in-a-subset-of-obese-women-without-diabetes
#10
RANDOMIZED CONTROLLED TRIAL
Jody Dushay, Chuanyun Gao, Gosala S Gopalakrishnan, Meghan Crawley, Emilie K Mitten, Elissa Wilker, Janet Mullington, Eleftheria Maratos-Flier
OBJECTIVE: To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women. RESEARCH DESIGN AND METHODS: Forty-one obese women (aged 48 ± 11 years and BMI 33.1 ± 4.1 kg/m(2)) participated in a 35-week randomized, double-blind, placebo-controlled, crossover study, including two 16-week treatment periods separated by a 3-week washout period. There was no lifestyle intervention...
January 2012: Diabetes Care
https://www.readbyqxmd.com/read/21957771/-is-there-any-relation-between-diabetes-therapy-and-cancer-risk
#11
REVIEW
S Svacina
Type 2 diabetes is associated with increased risk of cancer. This risk is related to HbA1 increase and this influence is present also in prediabetes and in nondiabetics with HbA1c in upper normal range. In last 2 years, it was concluded that that the specific antidiabetic therapy could influence the cancer risk. In this review we show that reduction of HbA1c does not change cancer risk. Most important is the risk reduction of cancer risk by metformin. Insulin therapy and the use ofsulphonylurea related drugs, increases the risk of cancer...
September 2011: Vnitr̆ní Lékar̆ství
https://www.readbyqxmd.com/read/21437094/emerging-role-of-glp-1-receptor-agonists-in-the-treatment-of-obesity
#12
Lisa M Neff, Robert F Kushner
The prevalence of obesity has increased dramatically in recent decades, both in the US and worldwide. Pharmacotherapy can augment the weight-reducing effects of lifestyle modification and can facilitate long-term weight maintenance. However, there is a paucity of pharmacologic agents approved for the treatment of obesity, and the use of existing weight loss medications is frequently limited by contraindications, drug interactions, adverse effects, limited coverage by third-party payers, and cost. In recent years, there has been an increased understanding and appreciation of the role of gastrointestinal hormones in the control of body weight...
2010: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
https://www.readbyqxmd.com/read/21312223/novel-glp-1-mimetics-developed-to-treat-type-2-diabetes-promote-progenitor-cell-proliferation-in-the-brain
#13
A Hamilton, S Patterson, D Porter, V A Gault, C Holscher
One of the symptoms of diabetes is the progressive development of neuropathies. One mechanism to replace neurons in the CNS is through the activation of stem cells and neuronal progenitor cells. We have tested the effects of the novel GLP-1 mimetics exenatide (exendin-4; Byetta) and liraglutide (NN2211; Victoza), which are already on the market as treatments for type 2 diabetes, on the proliferation rate of progenitor cells and differentiation into neurons in the dentate gyrus of brains of mouse models of diabetes...
April 2011: Journal of Neuroscience Research
https://www.readbyqxmd.com/read/20682680/acute-pancreatitis-in-type-2-diabetes-treated-with-exenatide-or-sitagliptin-a-retrospective-observational-pharmacy-claims-analysis
#14
Rajesh Garg, William Chen, Merri Pendergrass
OBJECTIVE: Cases of acute pancreatitis have been reported in association with exenatide, sitagliptin, and type 2 diabetes without use of these medications. It remains unknown whether exenatide or sitagliptin increase the risk of acute pancreatitis. RESEARCH DESIGN AND METHODS: A retrospective cohort study of a large medical and pharmacy claims database was performed. Data for 786,656 patients were analyzed. Cox proportional hazard models were built to compare the risk of acute pancreatitis between diabetic and nondiabetic subjects and between exenatide, sitagliptin, and control diabetes medication use...
November 2010: Diabetes Care
https://www.readbyqxmd.com/read/20332357/effects-of-exenatide-and-lifestyle-modification-on-body-weight-and-glucose-tolerance-in-obese-subjects-with-and-without-pre-diabetes
#15
RANDOMIZED CONTROLLED TRIAL
Julio Rosenstock, Leslie J Klaff, Sherwyn Schwartz, Justin Northrup, John H Holcombe, Kenneth Wilhelm, Michael Trautmann
OBJECTIVE: To assess the effects of exenatide on body weight and glucose tolerance in nondiabetic obese subjects with normal or impaired glucose tolerance (IGT) or impaired fasting glucose (IFG). RESEARCH DESIGN AND METHODS: Obese subjects (n = 152; age 46 +/- 12 years, female 82%, weight 108.6 +/- 23.0 kg, BMI 39.6 +/- 7.0 kg/m(2), IGT or IFG 25%) were randomized to receive exenatide (n = 73) or placebo (n = 79), along with lifestyle intervention, for 24 weeks...
June 2010: Diabetes Care
https://www.readbyqxmd.com/read/17213311/a-nonpeptidic-agonist-of-glucagon-like-peptide-1-receptors-with-efficacy-in-diabetic-db-db-mice
#16
Desu Chen, Jiayu Liao, Na Li, Caihong Zhou, Qing Liu, Guangxing Wang, Rui Zhang, Song Zhang, Lilin Lin, Kaixian Chen, Xin Xie, Fajun Nan, Andrew A Young, Ming-Wei Wang
Peptidic mimics of the gut hormone glucagon-like peptide (GLP) 1, exemplified by the recently approved drug exenatide, show promise as therapies for type 2 diabetes. Such "incretin mimetics" regulate glucose appearance in the plasma and can restore glucose-stimulated insulin secretion without excess risk of hypoglycemia. The need for injection, which may limit the use of peptidic GLP-1 receptor (GLP-1R) agonists, has driven largely unsuccessful efforts to find smaller molecules. The failure to identify orally effective agonists has instead promoted the indirect approach of inhibiting the GLP-1-degrading enzyme dipeptidyl peptidase IV...
January 16, 2007: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/15618356/exenatide-exendin-4-improves-insulin-sensitivity-and-beta-cell-mass-in-insulin-resistant-obese-fa-fa-zucker-rats-independent-of-glycemia-and-body-weight
#17
Bronislava R Gedulin, Svetlana E Nikoulina, Pamela A Smith, George Gedulin, Loretta L Nielsen, Alain D Baron, David G Parkes, Andrew A Young
The effects of the incretin mimetic exenatide (exendin-4) on metabolic parameters, insulin sensitivity, and beta-cell mass were examined in nondiabetic, insulin-resistant obese fa/fa Zucker rats. After 6 wk of treatment, ad libitum-fed exenatide-treated (EX) and pair-fed vehicle control (PF) rats had comparable food intake, body weight, hemoglobin A(1c) (HbA(1c)), and fasting plasma concentrations of glucose, insulin, and lipids. Concurrent decreases in food intake and weight gain were observed in EX and PF rats, compared with ad libitum-fed vehicle control (CON) rats (P < 0...
April 2005: Endocrinology
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"